Answers are grounded in this paper and cite their sources.
Introduction Heart failure with preserved ejection fraction (HFpEf) is associated with a reduction in functional capacity and health-related quality of life. There have been difficulties in establishing Class I recommendations in the European Society of Cardiology Guidelines for treating HFpEF. With the recent emergence of SGLT2i's as a potential therapeutic for HFpEF, recent network meta-analyses have explored the effect of pharmacological therapies on cardiovascular mortality, morbidity and hospitalisations. Additionally, there is inconsistency in the statistical approach taken, with studies opting for either a solely Frequentist or Bayesian approach. We aim to provide a) a network-level analysis of pharmacotherapies on the functional capacity of the HFpEF population and b) a comparison of different network meta-analysis approaches. Methods We performed a systematic search of Ovid Medline, PubMed, EMBASE, CENTRAL and Clintrials.gov from inception until November 2023. Randomised controlled trials comparing pharmacological agents to a placebo or another pharmacological agent in an adult population with HFpEF were included. The outcome of interest was the standardised mean difference in change in baseline 6-minute walk distance (6MWD) to represent functional capacity. A random-effects network meta-analysis was conducted twice - first using a Bayesian approach with uninformative priors, and subsequently with a Frequentist approach. Results Sixteen studies were included, consisting of 3,852 patients with a mean age of 70.5 ± 9.3 and 50.1% male cohort. Our Bayesian network meta-analysis showed no statistically significant improvement in 6MWD compared to placebo. However, the Frequentist approach demonstrated a significant improvement in change from baseline 6MWD in GLP-1 (glucagon-like peptide 1) agonists (20.3, 95% CI [4.10, 36.50]) and pAR (partial adenosine A1 receptor) agonists (29.2, 95% CI [1.78, 56.62]) compared to placebo. Neither network meta-analysis approaches yielded a significant improvement in 6MWD for SGLT2i. Conclusion The inconsistency in statistical significance between models highlights the uncertainty of the evidence behind pharmacotherapies for improving functional capacity in HFpEF patients. Despite this, our analysis provides a few promising therapeutics as candidates for further investigation. Furthermore, we encourage greater clarity in approaches undertaken in network meta-analyses and clarification of discordant results. Conflict of Interest N/A
No takes yet. Share an insight, caveat, or question.
Qenami et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: